FundRx

FundRx, Inc is a venture capital firm based in New York, specializing in investments in startups and early-stage companies within the healthcare and life sciences sectors. The firm focuses on a diverse range of industries, including pharmaceuticals, medical devices, biotechnology, diagnostics, healthcare IT, and healthcare services. FundRx primarily targets companies located in the United States, Canada, the United Kingdom, and Israel, although it may consider opportunities in other regions as well. The firm typically invests a minimum of $20,000 in its portfolio companies and aims to take a 20% carried interest on successful exits. Through its strategic investments, FundRx is dedicated to fostering innovation in the healthcare landscape.

Dr Ruchi Dana

Venture Partner

9 past transactions

Lucy Goods

Series A in 2020
Lucy Goods, Inc. is a company based in Los Angeles, California, that specializes in manufacturing and selling nicotine alternatives to conventional tobacco products. Founded in 2016, Lucy Goods offers a range of products, including nicotine gum available in flavors such as fruit, mint, and cinnamon, as well as nicotine lozenges. The company focuses on providing next-generation nicotine products that utilize pure nicotine and food-grade ingredients, aiming to create a cleaner and more convenient alternative to existing market offerings. Lucy Goods is driven by a mission to eliminate tobacco-related harm entirely. The company's products are primarily sold through online channels.

CloudCath

Series A in 2020
CloudCath is a company that specializes in developing a sensor-enabled digital platform tailored for patients undergoing peritoneal dialysis. The platform integrates Internet of Things-based sensing hardware with a continuous monitoring system, allowing for the early detection of complications associated with catheter-based treatments. This innovative approach not only enhances patient care by enabling healthcare providers to monitor patients remotely during their home treatments but also aims to reduce the frequency of in-person visits required each month. By focusing on early complication detection, CloudCath seeks to improve patient outcomes in the management of dialysis therapy.

ixLayer

Series A in 2019
ixLayer is a leader in the health-tech sector, specializing in precision health testing solutions that facilitate virtual health testing for various stakeholders, including health systems, payors, biopharma, and health-focused organizations. Established in 2018, ixLayer's platform offers comprehensive solutions encompassing technical, security, regulatory, and user experience aspects of complex health testing. As the demand for remote and virtual care continues to grow, ixLayer enhances patient engagement and preventative health strategies by enabling real-time health and wellness lab testing. The platform can be seamlessly integrated with existing patient engagement systems and portals, allowing organizations to efficiently launch and manage testing programs. Serving millions of patients, ixLayer has developed and implemented numerous testing initiatives for large organizations, healthcare systems, and government agencies, contributing to a progressive shift towards telehealth.

Osmosis

Series A in 2019
Osmosis is a personalized learning platform focused on enhancing health education by providing a deeper understanding of medical concepts. The platform enables clinicians and caregivers to access a wealth of educational resources, including a comprehensive library of videos and multiple-choice questions. Driven by data and technology, Osmosis aims to improve retention and preparedness for courses and exams, making it a valuable tool for medical professionals seeking to deepen their knowledge and skills in the healthcare field. By offering tailored content that goes beyond traditional lectures, Osmosis supports effective learning for a global audience in the medical community.

Mightier

Series A in 2019
Mightier is a Boston-based gaming platform established in 2016 that focuses on helping children develop emotional regulation skills through bioresponsive video games. The company's innovative program, developed in collaboration with Boston Children's Hospital and Harvard Medical School, utilizes a heart rate monitor to create a unique gaming experience where the game's difficulty adjusts based on the player's emotional state. This approach allows children to visualize their emotions in real-time, enabling them to learn how to manage their feelings effectively. By engaging with these games, kids with behavioral and emotional challenges can discover their emotional strengths and improve their ability to cope with daily situations.

Contraline

Seed Round in 2018
Contraline, Inc. is a biotechnology company based in Charlottesville, Virginia, focused on developing innovative male birth control solutions. The company is pioneering the first long-lasting, non-hormonal, and reversible contraceptive for men. Its primary product, Echo-V, is an ultrasound-visible polymer solution that is injected into the vas deferens, forming a polymer hydrogel device. This device functions as a semi-permeable membrane, effectively blocking sperm while allowing bodily fluids to pass through. Contraline also offers Vasintomy, a non-surgical procedure for the insertion of Echo-V, providing a cost-effective and accessible approach to male contraception. Incorporated in 2015, Contraline aims to transform the landscape of reproductive health for men.

Wellth

Seed Round in 2018
Wellth is a digital health company based in New York that operates a mobile application aimed at improving treatment adherence among individuals with chronic conditions. The platform leverages principles from behavioral economics to address the unique challenges faced by these patients in establishing healthy habits and managing their diseases. By offering targeted incentive plans, reminders, and valuable information, Wellth encourages consumers to take proactive steps toward their health, thus reducing overall healthcare costs. The application's design fosters motivation and behavior change, as it is supported by evidence from randomized controlled trials demonstrating its effectiveness. Wellth's approach has been validated by health plans and providers, resulting in improved medication adherence, reduced hospital readmissions, and better health outcomes for users.

Buoy Health

Series A in 2017
Buoy Health, Inc. is a health technology company based in Boston, Massachusetts, with an additional office in New York City. Founded in 2014, Buoy Health develops an artificial intelligence-driven digital health solution designed to empower individuals in managing their health and navigating the healthcare system. The company's primary offering, Buoy Health, is an online healthcare chatbot that provides personalized symptom analysis, facilitates first-line triage, and offers treatment recommendations. This platform functions as a comprehensive resource, enabling users to engage in self-diagnosis and access information about health benefits. Additionally, Buoy Health can be customized for employers to help employees find in-network providers and access wellness programs, thereby enhancing the overall healthcare experience.

Sonavex

Series A in 2017
Sonavex, Inc. is a medical technology company based in Baltimore, Maryland, founded in 2013. The company specializes in developing innovative imaging solutions, primarily focusing on ultrasound-based methods to detect anastomotic blood clots and assess vascular health. Sonavex's proprietary technology platform provides clinicians with real-time visualization of critical data at the point of care, enabling them to measure intravascular flow metrics and detect post-operative clots effectively. Additionally, the company has developed bioresorbable and echogenic equipment designed to mark at-risk blood vessels, allowing for future assessments of complications. This technology collects essential data, such as volumetric flow rate and vessel morphology, to enhance patient care in surgical settings, ultimately aiming to improve outcomes for surgical patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.